September 25, 2019

Antisense Therapeutics Announces Positive Preliminary Results from ATL1102 for Duchenne Phase II Trial

Antisense Therapeutics has announced that a review of the preliminary data from the 6 patients who have completed their 24 weeks of dosing in the Phase II clinical trial of the company’s immunomodulatory therapy, ATL1102…

Learn More

September 25, 2019

Santhera Shares Fall 2019 Community Update

Santhera has shared a community update on the company’s Duchenne drug development programs and their partnership with ReveraGen. Click here to download.

Learn More

September 24, 2019

End Duchenne Tour Recap: Wilmington, Delaware

PPMD’s End Duchenne Tour made a stop in Wilmington, Delaware on September 14. We were joined by over 100 people, including 30 families, 20 healthcare professionals and researchers, 15 industry partners, and 5 members of…

Learn More

September 24, 2019

Coach To Cure MD Is This Weekend!

In honor of Coach To Cure MD, presented by Werner Ladder, on Saturday, September 28, we need YOU to join our team to help us #TackleDuchenne! Making forward progress is easy — just take a photo in…

Learn More

September 23, 2019

Italfarmaco Shares Fall 2019 Newsletter

Italfarmaco has shared the Fall 2019 issue of their newsletter, including updates on the Givinostat Development Program. Click here to download.

Learn More

September 19, 2019

PPMD Announces First Adult Certified Duchenne Care Center, University of Missouri Health Care

Today Parent Project Muscular Dystrophy (PPMD) announced the expansion of our Certified Duchenne Care Center Program (CDCCP) with the program’s first Adult Certified Duchenne Care Center, the clinic at University of Missouri Health Care (MU…

Learn More

September 18, 2019

Recap of PPMD’s Duchenne Platform Trial Community Meeting

On Monday September 9, PPMD along with I-ACT for Children and the Duchenne Regulatory Science Consortium (DRSC) held an open meeting inviting all stakeholders (patients, families, industry sponsors, and regulators) in Duchenne to learn and…

Learn More

September 17, 2019

PPMD Awards University of Florida $1 Million for Novel Gene Therapy Approach Targeting the Heart

As you know, one of PPMD’s priorities in the fight to end Duchenne is maintaining cardiac health and preventing heart disease or dilated cardiomyopathy (DCM), better known as heart failure in Duchenne muscular dystrophy. Heart…

Learn More

September 16, 2019

Wave Life Sciences Announces Fast Track Designation from U.S. FDA for Suvodirsen

Wave Life Sciences shared today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to suvodirsen for the treatment of Duchenne in patients amenable to exon 51 skipping. Fast Track designation…

Learn More

September 16, 2019

PPMD Unveils Care Materials & Remote Tour Stop in SPANISH

Each year during Duchenne Action Month, PPMD reminds our families to download our comprehensive care materials, including critical emergency information. This information is especially important as kids head back to school to help educate school staff….

Learn More